


Ctudy	J^2			Oddo Potio (05% Crl)	
Study			I	Odds Ratio (95% Crl)	
Afatinib_Cetuximab vs A	fatinib				
29			<del></del>	1.0 (0.41, 2.6)	
Pooled (pair-wise)			<del></del>	1.1 (0.22, 4.8)	
Indirect (back-calculated)				NA	
Pooled (network)			<del></del>	1.0 (0.32, 3.3)	
Afatinib_HMGCRi vs Afatinib					
40			<del></del>	1.5 (0.36, 6.4)	
Pooled (pair-wise)				1.5 (0.24, 11.)	
Indirect (back-calculated)				NA	
Pooled (network)				1.5 (0.29, 7.6)	
Chemotherapy vs Afatini	ib				
50				2.1 (0.22, 20.)	
57		$\leftarrow$		> 3.8e+14 (2.9e-07, 4.9e+35)	
Pooled (pair-wise)	47.9%			→ 3.6 (0.47, 41.)	
Indirect (back-calculated)				1.0 (0.42, 2.5)	
Pooled (network)	8.3%		<del></del>	1.2 (0.53, 2.7)	
Erlotinib vs Afatinib					
38			<del></del>	0.99 (0.48, 2.0)	
Pooled (pair-wise)				0.99 (0.23, 4.2)	
Indirect (back-calculated)				1.1 (0.46, 2.6)	
Pooled (network)	0.0%			1.1 (0.53, 2.3)	
Gefitinib vs Afatinib					
48				0.99 (0.30, 3.3)	
Pooled (pair-wise)				1.0 (0.18, 5.6)	
Indirect (back-calculated)				0.78 (0.29, 2.1)	
Pooled (network)	0.0%			0.83 (0.35, 2.0)	
		2.00		٦ ` ` ` ′	
		0.03	1	30	





Study	I^2			Odds Ratio (95% Crl)		
Osimertinib vs Chemotherapy						
42			<del>                                     </del>	2.9 (0.76, 11.)		
Pooled (pair-wise)			-	- 2.8 (0.52, 21.)		
Indirect (back-calculated)				1.7 (0.62, 4.7)		
Pooled (network)	0.0%		<del>  -</del>	1.9 (0.80, 4.8)		
Erlotinib vs Dacomitinib						
59			+-	1.5 (0.80, 2.9)		
Pooled (pair-wise)			<del></del>	1.5 (0.36, 6.2)		
Indirect (back-calculated)				2.0 (0.73, 5.7)		
Pooled (network)	0.0%		<del>  •</del>	1.8 (0.84, 4.5)		
<b>Gefitinib vs Dacomitinib</b>						
43			<del></del>	→ 1.0 (0.031, 36.)		
Pooled (pair-wise)			-	→ 1.2 (0.034, 68.)		
Indirect (back-calculated)			····∤⊙·····	1.5 (0.49, 4.4)		
Pooled (network)	0.0%		<del></del>	1.4 (0.50, 4.2)		
Placebo vs Dacomitinib						
r6			<del>  • • • • • • • • • • • • • • • • • • •</del>	2.6 (0.63, 10.)		
Pooled (pair-wise)				2.6 (0.42, 17.)		
Indirect (back-calculated)			ф	0.99 (0.35, 2.8)		
Pooled (network)	18.3%		<del></del>	1.2 (0.50, 3.1)		
Erlotinib vs DHFRi						
r18			<del></del>	1.4 (0.26, 7.1)		
Pooled (pair-wise)			<del></del>	1.3 (0.18, 11.)		
Indirect (back-calculated)				NA		
Pooled (network)			-	1.4 (0.23, 8.1)		
		0.03	1	30		
Pooled (pair-wise) Indirect (back-calculated) Pooled (network)  Gefitinib vs Dacomitinib  43 Pooled (pair-wise) Indirect (back-calculated) Pooled (network)  Placebo vs Dacomitinib  r6 Pooled (pair-wise) Indirect (back-calculated) Pooled (network)  Erlotinib vs DHFRi  r18 Pooled (pair-wise) Indirect (back-calculated)	0.0%	0.03		1.5 (0.36, 6.2) 2.0 (0.73, 5.7) 1.8 (0.84, 4.5) → 1.0 (0.031, 36.) → 1.2 (0.034, 68.) 1.5 (0.49, 4.4) 1.4 (0.50, 4.2) 2.6 (0.42, 17.) 0.99 (0.35, 2.8) 1.2 (0.50, 3.1) 1.4 (0.26, 7.1) 1.3 (0.18, 11.) NA 1.4 (0.23, 8.1)		



Study **I**^2 Odds Ratio (95% Crl) **Erlotinib HGFi vs Erlotinib** 56  $\rightarrow$  9.7e-19 (1.1e-44, 8.8e+07) Pooled (pair-wise) 3.2e-15 (1.2e-46, 0.074) NA Indirect (back-calculated) Pooled (network) 5.9e-13 (5.1e-28, 0.10) Erlotinib\_IGF\_1Ri vs Erlotinib 44 0.82 (0.44, 1.5) 9 → 6.1e+16 (0.00031, 1.2e+37) Pooled (pair-wise) 76.2% 1.2 (0.47, 6.1) Indirect (back-calculated) NA Pooled (network) 1.1 (0.51, 3.1) 72.2% **Erlotinib METi vs Erlotinib** 12 2.2 (1.1, 4.4) 39  $\rightarrow$  0.99 (0.028, 34.) 1.3 (0.46, 3.7) Pooled (pair-wise) 0.0% 1.7 (0.59, 4.4) Indirect (back-calculated) NA Pooled (network) 0.0% 1.7 (0.79, 3.6) **Erlotinib** MMPi vs Erlotinib 21 3.8 (0.64, 23.) Pooled (pair-wise) 3.8 (0.50, 44.) Indirect (back-calculated) NA Pooled (network) 3.4 (0.64, 30.) 0.03 30

Study	I^2		Odds Ratio (95% Crl)				
Erlotinib_antiangio vs Erlotinib							
15 16 2 25 33 34 35 36			0.15 (0.0093, 2.4) 2.4 (0.86, 6.6) 0.37 (0.019, 7.3) 1.1 (0.72, 1.7) 0.38 (0.10, 1.4) 1.2 (0.54, 2.5) 6.2 (1.1, 36.) 1.1 (0.11, 10.)				
37 41		$\leftarrow$	2.6e+09 (8.0e-35, 8.7e+52) 1.9e-18 (1.7e-44, 2.1e+08)				
Pooled (pair–wise) Indirect (back–calculated)	31.0%		1.1 (0.55, 1.9) NA				
Pooled (network)	30.6%	<del>-</del>	1.1 (0.70, 1.7)				
Placebo vs Erlotinib							
30 46 58 Pooled (pair–wise) Indirect (back–calculated)	0.0%	•	0.16 (0.010, 2.5) 0.94 (0.33, 2.7) 0.41 (0.062, 2.7) 0.59 (0.17, 1.7) 0.73 (0.33, 1.6)				
Pooled (network)	0.0%	<del></del>	0.68 (0.33, 1.2)				
Rociletinib vs Erlotinib							
53 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		0.03 1 30	5.9 (2.3, 15.) 6.0 (1.3, 28.) NA 6.0 (1.8, 20.)				

